A new wave of synthetic opioids is alarming doctors and public health officials across the country as emergency rooms report ...

(WKBN) – Every year, thousands of people die from overdosing on opioids in the U.S. but now there’s a new, non-opioid pain medication that’s just been approved by the FDA. Suzetrigine is the first ...

While the dangers of fentanyl have been dominating headlines for years, the death toll from another class of extremely potent synthetic opioids called "nitazenes" has been climbing steadily. For ...

The opioid epidemic has affected hospitals, both clinically and financially, for almost 30 years. More than1,000 acute care hospitals will receive a share of $700 million as part of the settlement of ...

Pennsylvania Republican Sen. David McCormick is cosponsoring a new bill that would permanently tighten restrictions of an emerging group of synthetic opioids, known as nitazenes, that are more potent ...

The Supreme Court’s ruling maintains the decisions of the lower courts (see our recent article) and allows the Government of British Columbia to continue pursuing its proposed “multi-Crown” class ...

In a milestone moment for chronic pain management, Tonix Pharmaceuticals announced on August 15, 2025, that its novel ...

The next generation of physician assistants spent the day Friday learning how to treat opioid addiction at the University of Washington MEDEX Northwest PA School in Kealakekua. “What we are teaching ...

This is the first new type of pain medication to be approved in more than 20 years It is anticipated that payers will see an up-tick in the number of requests for this new drug. Journavx will likely ...

Kristyna Wentz-Graff / OPB Oregon public health officials are mapping out plans for spending $41 million in opioid settlement funding that will go toward preventing addiction, expanding treatment ...

Sonja Verdugo lost her husband to an opioid overdose last year. She regularly delivers medical supplies to people using drugs who are living — and dying — on the streets of Los Angeles. And she ...